Catalyst Wire Dossier Catalyst Wire Dossier

AMT-162

· UniQure Biopharma B.V.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AMT-162, covering 2025-10-22 to 2025-10-22. Get the full timeline:

Most recent: Clinical Trial Update: Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) [Phase 1, Phase 2]

See pricing